• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

溶瘤性水疱性口炎病毒单独或与JAK抑制剂联合使用对卵巢癌有效。

Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer.

作者信息

Geoffroy Karen, Mullins-Dansereau Victor, Leclerc-Desaulniers Kim, Viens Mélissa, Bourgeois-Daigneault Marie-Claude

机构信息

Cancer and Immunopathology Axes, CHUM Research Centre, Montreal, QC H2X 0A9, Canada.

Institut du cancer de Montréal, Montreal, QC H2X 0A9, Canada.

出版信息

Mol Ther Oncol. 2024 Jun 8;32(3):200826. doi: 10.1016/j.omton.2024.200826. eCollection 2024 Sep 19.

DOI:10.1016/j.omton.2024.200826
PMID:39006945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11246050/
Abstract

Therapy-resistant ovarian cancers have a poor prognosis and novel effective treatment options are urgently needed. In this study, we evaluated the therapeutic efficacy of the oncolytic vesicular stomatitis virus (VSV) against a panel of patient-derived ovarian cancer cell lines of all epithelial subtypes. Notably, we found that most of the cell lines were sensitive to VSV virotherapy. With the objective of improving treatment efficacy for the oncolytic virus-resistant cell lines, we tested various combinations with ovarian cancer standard of care drugs: olaparib, carboplatin, paclitaxel, doxorubicin, cyclophosphamide, and gemcitabine. While none of these combinations revealed to be beneficial, further experiments demonstrated that the antiviral interferon pathway was functional in VSV-resistant cell lines. Given that interferons signal through Janus kinase (JAK)-STAT to mediate their antiviral function, we tested combinations of oncolytic VSV with clinically relevant JAK inhibitors. Our results show that combining VSV with various JAK inhibitors, including ruxolitinib, enhances VSV virotherapy and treatment efficacy. Altogether, we show that VSV, either as a stand-alone treatment or in combination with JAK inhibitors provides an effective therapeutic option for ovarian cancer patients.

摘要

对治疗耐药的卵巢癌预后较差，迫切需要新的有效治疗方案。在本研究中，我们评估了溶瘤性水疱性口炎病毒（VSV）对一组源自患者的所有上皮亚型卵巢癌细胞系的治疗效果。值得注意的是，我们发现大多数细胞系对VSV病毒疗法敏感。为了提高对溶瘤病毒耐药的细胞系的治疗效果，我们测试了VSV与卵巢癌标准护理药物的各种联合使用情况：奥拉帕利、卡铂、紫杉醇、多柔比星、环磷酰胺和吉西他滨。虽然这些联合使用均未显示出有益效果，但进一步实验表明抗病毒干扰素途径在VSV耐药细胞系中发挥作用。鉴于干扰素通过Janus激酶（JAK）-信号转导子和转录激活子（STAT）信号通路介导其抗病毒功能，我们测试了溶瘤性VSV与临床相关JAK抑制剂的联合使用情况。我们的结果表明，VSV与包括鲁索替尼在内的各种JAK抑制剂联合使用可增强VSV病毒疗法及治疗效果。总之，我们表明VSV无论是单独治疗还是与JAK抑制剂联合使用，都为卵巢癌患者提供了一种有效的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/f18636ad8d3b/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/aafe391264f9/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/8dd0ff742c5b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/5eed1d2b8f2b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/287dd7f0894a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/2de0e17adbd6/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/75daa623119d/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/f18636ad8d3b/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/aafe391264f9/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/8dd0ff742c5b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/5eed1d2b8f2b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/287dd7f0894a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/2de0e17adbd6/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/75daa623119d/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d7/11246050/f18636ad8d3b/gr6.jpg

相似文献

1
Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer.溶瘤性水疱性口炎病毒单独或与JAK抑制剂联合使用对卵巢癌有效。
Mol Ther Oncol. 2024 Jun 8;32(3):200826. doi: 10.1016/j.omton.2024.200826. eCollection 2024 Sep 19.
2
JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.JAK/STAT 抑制用芦可替尼增强非小细胞肺癌模型中的溶瘤病毒治疗。
Cancer Gene Ther. 2019 Nov;26(11-12):411-418. doi: 10.1038/s41417-018-0074-6. Epub 2019 Jan 9.
3
Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.芦可替尼与聚阳离子联合治疗克服了胰腺癌细胞对溶瘤性水疱性口炎病毒的多种耐药机制。
J Virol. 2017 Jul 27;91(16). doi: 10.1128/JVI.00461-17. Print 2017 Aug 15.
4
Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.使用 JAK1/2 抑制剂克服癌细胞对 VSV 溶瘤的抵抗。
Cancer Gene Ther. 2013 Oct;20(10):582-9. doi: 10.1038/cgt.2013.55. Epub 2013 Sep 13.
5
Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.胰腺癌细胞对溶瘤性水疱性口炎病毒耐药的新型生物标志物。
Oncotarget. 2016 Sep 20;7(38):61601-61618. doi: 10.18632/oncotarget.11202.
6
Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.肿瘤间异质性影响溶瘤性水疱性口炎病毒在小鼠胰腺癌细胞中的疗效。
J Virol. 2023 Sep 28;97(9):e0100523. doi: 10.1128/jvi.01005-23. Epub 2023 Sep 6.
7
Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.β干扰素和α2a干扰素对头部和颈部癌细胞免受水疱性口炎病毒诱导的肿瘤溶解具有不同的保护作用。
J Virol. 2015 Aug;89(15):7944-54. doi: 10.1128/JVI.00757-15. Epub 2015 May 20.
8
Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions.扩大对基于水疱性口炎病毒的溶瘤病毒疗法有反应的胰腺癌谱：挑战与解决方案
Cancers (Basel). 2021 Mar 9;13(5):1171. doi: 10.3390/cancers13051171.
9
Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.通过IKK抑制剂TPCA-1的新活性打破胰腺癌细胞对减毒水疱性口炎病毒的抗性。
Virology. 2015 Nov;485:340-54. doi: 10.1016/j.virol.2015.08.003. Epub 2015 Aug 29.
10
Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.胰腺癌对溶瘤单纯疱疹病毒的耐药性：I 型干扰素信号的作用。
Virology. 2013 Feb 5;436(1):221-34. doi: 10.1016/j.virol.2012.11.014. Epub 2012 Dec 14.

引用本文的文献

1
Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.卵巢癌中的溶瘤病毒：我们目前的进展如何？一篇叙述性综述。
Pathogens. 2025 Feb 3;14(2):140. doi: 10.3390/pathogens14020140.
2
Employing the Oncolytic Vesicular Stomatitis Virus in Cancer Virotherapy: Resistance and Clinical Considerations.溶瘤性水疱性口炎病毒在癌症病毒治疗中的应用：耐药性及临床考量
Viruses. 2024 Dec 25;17(1):16. doi: 10.3390/v17010016.
3
The Small GTPase Ran Increases Sensitivity of Ovarian Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

本文引用的文献

1
Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy.新型溶瘤单纯疱疹病毒联合紫杉醇治疗乳腺癌的疗效研究
J Med Virol. 2023 May;95(5):e28768. doi: 10.1002/jmv.28768.
2
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review.鲁索替尼的药代动力学和药效学：综述。
Clin Pharmacokinet. 2023 Apr;62(4):559-571. doi: 10.1007/s40262-023-01225-7. Epub 2023 Mar 31.
3
Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers.
小GTP酶Ran增强卵巢癌细胞对溶瘤性水疱性口炎病毒的敏感性。
Pharmaceuticals (Basel). 2024 Dec 10;17(12):1662. doi: 10.3390/ph17121662.
癌细胞中免疫蛋白酶体亚基 PSMB8 和 PSMB9 的表达增加与三阴性乳腺癌的更好预后相关。
Sci Rep. 2023 Feb 6;13(1):2129. doi: 10.1038/s41598-023-28940-2.
4
The role of interferons in ovarian cancer progression: Hinderer or promoter?干扰素在卵巢癌进展中的作用：阻碍还是促进？
Front Immunol. 2022 Dec 21;13:1087620. doi: 10.3389/fimmu.2022.1087620. eCollection 2022.
5
Mechanisms of chemotherapy resistance in ovarian cancer.卵巢癌化疗耐药的机制
Cancer Drug Resist. 2022 Apr 3;5(2):304-316. doi: 10.20517/cdr.2021.147. eCollection 2022.
6
A Comprehensive Overview of Globally Approved JAK Inhibitors.全球获批的JAK抑制剂综合概述
Pharmaceutics. 2022 May 6;14(5):1001. doi: 10.3390/pharmaceutics14051001.
7
Cancer statistics, 2022.癌症统计数据，2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
8
Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.辅助溶瘤病毒治疗用于个体化抗肿瘤免疫治疗。
Nat Commun. 2021 May 11;12(1):2626. doi: 10.1038/s41467-021-22929-z.
9
Current Ovarian Cancer Maintenance Strategies and Promising New Developments.当前卵巢癌维持治疗策略及有前景的新进展
J Cancer. 2021 Jan 1;12(1):38-53. doi: 10.7150/jca.49406. eCollection 2021.
10
Doxorubicin hydrochloride enhanced antitumour effect of CEA-regulated oncolytic virotherapy in live cancer cells and a mouse model.盐酸多柔比星增强了 CEA 调控的溶瘤病毒治疗在活癌细胞和小鼠模型中的抗肿瘤作用。
J Cell Mol Med. 2020 Nov;24(22):13431-13439. doi: 10.1111/jcmm.15966. Epub 2020 Oct 14.